suramin has been researched along with paclitaxel in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (28.00) | 18.2507 |
| 2000's | 13 (52.00) | 29.6817 |
| 2010's | 5 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Coffey, DS; Pienta, KJ | 1 |
| Reed, E | 1 |
| Nishio, K; Nomoto, T; Saijo, N | 1 |
| Cheson, BD | 1 |
| Kaufmann, SH; Rowinsky, EK | 1 |
| Chahinian, AP; Gluck, H; Holland, JF; Mandeli, JP; Naim, H; Teirstein, AS | 1 |
| Emanuele, S; Giuliano, M; Lauricella, M; Tesoriere, G; Vento, R | 1 |
| Au, JL; Gan, Y; Song, S; Wientjes, MG | 1 |
| Iñiguez, C; Larrodé, P; Mauri, JA; Mayordomo, JI; Morales, F; Trés, A | 1 |
| Au, JL; Song, S; Walsh, C; Wientjes, MG | 1 |
| Heicappell, R | 1 |
| Peltier, AC; Russell, JW | 1 |
| Au, JL; Chen, D; DeHoff, C; Fischer, B; Grever, M; Kanter, S; Murgo, AJ; Otterson, GA; Song, S; Villalona-Calero, MA; Wientjes, MG; Yeh, TK; Young, D | 1 |
| Au, JL; Song, S; Wei, Y; Wientjes, MG; Yu, B | 1 |
| Gotfryd, K; Jurek, A; Klein, A; Kubit, P; Siaśkiewicz, A; Turyna, B | 1 |
| Au, JL; Lu, Z; Wientjes, TS | 1 |
| Au, JL; Chen, D; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Song, SH; Villalona-Calero, M; Wientjes, MG; Yeh, TK; Zhao, L | 1 |
| Au, JL; Bekaii-Saab, T; Eng, C; Grever, M; Jensen, R; Murgo, AJ; Otterson, GA; Villalona-Calero, MA; Weber, F; Wei, Y; Wientjes, MG; Yeh, TK; Young, D; Zhang, Y | 1 |
| Fu, Y; Nie, H; Wang, CH | 1 |
| Arifin, DY; Dong, Z; Hu, Y; Nie, H; Wang, CH | 1 |
| Au, JL; Berger, M; Brenner, L; Chen, L; Grever, M; Jensen, RR; Lustberg, MB; Mrozek, E; Pant, S; Ramaswamy, B; Ruppert, AS; Shapiro, CL; Shen, T; Shiels, D; Wei, Y; Wientjes, MG | 1 |
| Bondareva, A; Jirik, FR; Singla, AK | 1 |
8 review(s) available for suramin and paclitaxel
| Article | Year |
|---|---|
Cell motility as a chemotherapeutic target.
Topics: Animals; Antibodies; Antineoplastic Agents, Phytogenic; Cell Division; Cell Movement; Cytoskeleton; Male; Paclitaxel; Prostatic Neoplasms; Rats; Suramin; Vinblastine; Vincristine | 1991 |
Promising new developments in the systemic treatment of ovarian cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Female; Granulocyte Colony-Stimulating Factor; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Suramin | 1994 |
[Cell cycle regulation by anticancer agent].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell-Free System; Cisplatin; Cyclin-Dependent Kinases; G2 Phase; Humans; Paclitaxel; Suramin | 1995 |
New chemotherapeutic agents for the treatment of low-grade non-Hodgkin's lymphomas.
Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Depsipeptides; Gallium; Humans; Lymphoma, Non-Hodgkin; Mitoguazone; Paclitaxel; Peptides, Cyclic; Suramin | 1993 |
Topotecan in combination chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Humans; Paclitaxel; Suramin; Topoisomerase I Inhibitors; Topotecan | 1997 |
[Peripheral nervous system neurotoxicity secondary to chemotherapy treatment] .
Topics: Anti-HIV Agents; Antineoplastic Agents; Cyclosporine; Depsipeptides; Docetaxel; Doxorubicin; Humans; Neoplasms; Neuromuscular Diseases; Oligopeptides; Organoplatinum Compounds; Paclitaxel; Peripheral Nervous System Diseases; Procarbazine; Reverse Transcriptase Inhibitors; Suramin; Taxoids; Vinca Alkaloids | 2000 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Taxoids; Testosterone; Treatment Outcome | 2002 |
Recent advances in drug-induced neuropathies.
Topics: Animals; Antineoplastic Agents; Cisplatin; Humans; Immunosuppressive Agents; Paclitaxel; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Suramin; Vincristine | 2002 |
3 trial(s) available for suramin and paclitaxel
| Article | Year |
|---|---|
Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Suramin; Time Factors | 2003 |
Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Synergism; Female; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Suramin | 2008 |
Phase I/II trial of non-cytotoxic suramin in combination with weekly paclitaxel in metastatic breast cancer treated with prior taxanes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fibroblast Growth Factor 2; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Paclitaxel; Suramin; Taxoids; Treatment Outcome | 2012 |
14 other study(ies) available for suramin and paclitaxel
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Female; Fibrosarcoma; Humans; Mesothelioma; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Pleural Neoplasms; Sarcoma; Suramin; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Apoptotic effects of different drugs on cultured retinoblastoma Y79 cells.
Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Butyrates; Butyric Acid; Camptothecin; Carboplatin; Cisplatin; DNA Damage; Drug Screening Assays, Antitumor; Etoposide; Humans; Paclitaxel; Retinoblastoma; Suramin; Tumor Cells, Cultured | 1998 |
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubicin; Drug Resistance, Neoplasm; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Rats; Suramin; Tumor Cells, Cultured | 2000 |
Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Culture Media, Conditioned; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Rats; Suramin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Body Weight; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Drug Synergism; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Suramin; Time Factors; Treatment Outcome | 2004 |
Peritonitis-induced antitumor activity of peritoneal macrophages from uremic patients.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Humans; Macrophages, Peritoneal; Neoplasms; Paclitaxel; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Suramin; Uremia | 2004 |
Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Paclitaxel; Suramin; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
Nontoxic suramin as a chemosensitizer in patients: dosing nomogram development.
Topics: Algorithms; Antineoplastic Agents; Blood Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lung Neoplasms; Male; Models, Biological; Nomograms; Paclitaxel; Protein Binding; Reproducibility of Results; Suramin | 2006 |
Paclitaxel and suramin-loaded core/shell microspheres in the treatment of brain tumors.
Topics: Animals; Apoptosis; Biological Assay; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Luminescent Measurements; Male; Mice; Mice, Nude; Microscopy, Electron, Scanning; Microspheres; Paclitaxel; Subcutaneous Tissue; Suramin; Xenograft Model Antitumor Assays | 2010 |
Core/shell microspheres via coaxial electrohydrodynamic atomization for sequential and parallel release of drugs.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line; Drug Carriers; Drug Compounding; Drug Delivery Systems; Electrochemical Techniques; Lactic Acid; Materials Testing; Microspheres; Paclitaxel; Pharmaceutical Preparations; Polyesters; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Rats; Suramin | 2010 |
Combined treatment with paclitaxel and suramin prevents the development of metastasis by inhibiting metastatic colonization of circulating tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplastic Cells, Circulating; Paclitaxel; Suramin; Xenograft Model Antitumor Assays | 2014 |